The role of brain-derived neurotrophic factor and the neurotrophin receptor p75NTR in age-related brain atrophy and the transition to Alzheimer’s disease
Author:
Cade Shaun1, Zhou Xin-Fu1, Bobrovskaya Larisa1
Affiliation:
1. Health and Biomedical Innovation, Clinical and Health Sciences, University of South Australia , Adelaide , SA 5000 , Australia
Abstract
Abstract
Alzheimer’s disease is a neurodegenerative condition that is potentially mediated by synaptic dysfunction before the onset of cognitive impairments. The disease mostly affects elderly people and there is currently no therapeutic which halts its progression. One therapeutic strategy for Alzheimer’s disease is to regenerate lost synapses by targeting mechanisms involved in synaptic plasticity. This strategy has led to promising drug candidates in clinical trials, but further progress needs to be made. An unresolved problem of Alzheimer’s disease is to identify the molecular mechanisms that render the aged brain susceptible to synaptic dysfunction. Understanding this susceptibility may identify drug targets which could halt, or even reverse, the disease’s progression. Brain derived neurotrophic factor is a neurotrophin expressed in the brain previously implicated in Alzheimer’s disease due to its involvement in synaptic plasticity. Low levels of the protein increase susceptibility to the disease and post-mortem studies consistently show reductions in its expression. A desirable therapeutic approach for Alzheimer’s disease is to stimulate the expression of brain derived neurotrophic factor and potentially regenerate lost synapses. However, synthesis and secretion of the protein are regulated by complex activity-dependent mechanisms within neurons, which makes this approach challenging. Moreover, the protein is synthesised as a precursor which exerts the opposite effect of its mature form through the neurotrophin receptor p75NTR. This review will evaluate current evidence on how age-related alterations in the synthesis, processing and signalling of brain derived neurotrophic factor may increase the risk of Alzheimer’s disease.
Publisher
Walter de Gruyter GmbH
Subject
General Neuroscience
Reference133 articles.
1. Abner, E.L., Kryscio, R.J., Schmitt, F.A., Fardo, D.W., Moga, D.C., Ighodaro, E.T., Jicha, G.A., Yu, L., Dodge, H.H., Xiong, C., et al.. (2017). Outcomes after diagnosis of mild cognitive impairment in a large autopsy series. Ann. Neurol. 81: 549–559, https://doi.org/10.1002/ana.24903. 2. Aisen, P.S., Gauthier, S., Ferris, S.H., Saumier, D., Haine, D., Garceau, D., Duong, A., Suhy, J., Oh, J., Lau, W.C., et al.. (2011). Tramiprosate in mild-to-moderate Alzheimer’s disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch. Med. Sci. 7: 102–111, https://doi.org/10.5114/aoms.2011.20612. 3. Allard, S., Jacobs, M.L., Do Carmo, S., and Cuello, A.C. (2018). Compromise of cortical proNGF maturation causes selective retrograde atrophy in cholinergic nucleus basalis neurons. Neurobiol. Aging 67: 10–20, https://doi.org/10.1016/j.neurobiolaging.2018.03.002. 4. Alzheimer’s Association (2017). 2017 Alzheimer’s disease facts and figures. Alzheimer’s Dementia 13: 325–373. 5. Balkowiec, A. and Katz, D.M. (2002). Cellular mechanisms regulating activity-dependent release of native brain-derived neurotrophic factor from hippocampal neurons. J. Neurosci. 22: 10399–10407, https://doi.org/10.1523/jneurosci.22-23-10399.2002.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|